DOJ's 2026 Fraud Takedown Signals Data-Driven Enforcement

By Jake Leys

On June 23, 2026, the Department of Justice (DOJ) announced the results of its 2026 National Health Care Fraud Takedown, a record-setting coordinated health care fraud enforcement action in the Department's history. DOJ charged 455 defendants, including 90 physicians and other licensed medical professionals, in schemes involving more than $6.5 billion in alleged fraud, across 56 federal districts and 45 states and territories.

The numbers make for a great headline, but the more important story for compliance officers is the government’s increasingly sophisticated investigative approach. This year's Takedown reflects the growing scale and sophistication of the government’s shift from the old "pay-and-chase" model to real-time, data-driven prevention. Through the Centers for Medicare & Medicaid Services (CMS), the government suspended 1,079 providers, revoked billing privileges for 1,403 providers, and, according to DOJ, caught and suspended more than $10 billion in payments before the funds ever went out the door. DOJ credited "cutting-edge use of data analytics to target the worst actors," illustrating the government’s increasingly sophisticated use of claims data mining to proactively identify fraud and develop cases alongside traditional referrals and whistleblowers. 

At the same time that the government is expanding its own use of claims analytics, DOJ has moved to formalize its relationship with a growing class of data-driven whistleblowers. On April 30, 2026, DOJ's Civil Division launched the Fraud Oversight through Careful Use of Statistics (FOCUS) initiative, committing to prioritize working with the most rigorous whistleblower 'data miners' who analyze publicly available government data to identify fraud and file False Claims Act (FCA) qui tam suits. The practical takeaway: your billing data can generate enforcement scrutiny whether the analyst sits inside the government or outside.

The enforcement was record-breaking in its reach. Fifty state Medicaid Fraud Control Units participated, the most ever, alongside the Department of Health and Human Services Office of Inspector General (HHS-OIG), the Federal Bureau of Investigation, and the Drug Enforcement Administration (DEA). HHS-OIG excluded over 1,400 providers and announced 48 Civil Monetary Penalty settlements totaling over $73 million; the DEA initiated 928 administrative actions to revoke controlled-substance authority since October 1, 2025; and the government seized more than $182 million in cash, vehicles, and other assets. On the civil side, DOJ brought FCA charges against 13 defendants for $14.8 million and reached civil settlements with 31 defendants totaling $23 million.

Who Is Most Affected by DOJ’s Data-Driven Fraud Enforcement

The Takedown's fact patterns cut across the life sciences and provider landscape, but a few categories drew concentrated fire.

• Wound care and amniotic allografts. One of the most significant case categories involved amniotic wound allografts, placental-tissue products used to treat chronic wounds, with 11 defendants charged across six districts over allegedly unnecessary treatments and improper billing. Manufacturers, distributors, and providers in this space should anticipate heightened scrutiny.
• Telemedicine and digital health. International enforcement included the return of a defendant tied to a previously charged $1.2 billion telemedicine fraud scheme, underscoring DOJ’s continued pursuit of large-scale fraud schemes involving telemedicine and federal program reimbursement.
• Any entity billing federal programs. As the government is expanding its use of prospective claims analytics, aberrant billing patterns, even benign ones, could trigger audits or investigative scrutiny. Where the government identifies a credible allegation of fraud, those patterns may contribute to payment suspension. 

How Healthcare Organizations Should Proactively Respond to Data-Driven Enforcement

The increasing scale and sophistication of data-driven, pre-payment enforcement shifts the practical center of gravity away from responding to subpoenas and toward monitoring your own data before the government does.

1. Run your own analytics. Assume the government is comparing your billing against peer benchmarks. Identify outliers such as high-reimbursement codes, reflex or add-on testing, and utilization spikes, and document the clinical basis before a payment suspension forces the question.
2. Review high-risk service lines. Wound care, telehealth, laboratory, and durable medical equipment arrangements should get a fresh look at medical necessity, ordering protocols, and referral relationships.
3. Tighten overpayment procedures. With payments now being stopped pre-adjudication and CMS suspensions moving quickly, a documented process for promptly identifying, investigating, quantifying, and returning overpayments consistent with applicable CMS requirements is essential to limiting exposure.
4. Prepare for a payment suspension. Know who responds, how you preserve cash flow, and what rebuttal or appeal rights are available if a suspension or exclusion occurs.

How Gardner Law Can Help

Gardner Law advises pharmaceutical, medical device, laboratory, and digital health companies on the full arc of fraud-and-abuse risk, from proactive compliance assessments and internal data audits to responding to CMS payment suspensions, HHS-OIG exclusions, and DOJ investigations. We help clients assess billing, coding, referral, and compensation arrangements; conduct internal reviews of claims and utilization data; identify and investigate potential overpayments; and evaluate whether corrective action or self-disclosure may be appropriate. We also help clients stress-test their practices against current enforcement theories and build defensible documentation supporting compliant business and reimbursement decisions.

As government agencies increasingly use claims analytics and other data-driven tools to identify unusual billing patterns, companies should understand how their own data may appear to regulators. Gardner Law can help organizations identify potential outliers before they attract scrutiny, evaluate the clinical and operational explanations for those patterns, strengthen supporting documentation, and assess compliance controls in higher-risk service lines and reimbursement arrangements.

If you would like to understand how the government's increasingly sophisticated data-driven enforcement model affects your organization, contact us.